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Maintaining the appropriate complement and content of lipids in cellular membranes is critical for normal
neural function. Accumulating evidence suggests that even subtle perturbations in the lipid content of neurons
and myelin can disrupt their function and may contribute to myelin and axonal degradation. In this study, we
determined the composition and quantified the content of lipids and sterols in normal appearing white matter
(NAWM) and normal appearing grey matter (NAGM) from control and multiple sclerosis brain tissues by elec-
trospray ionization tandem mass spectrometry.Our results suggest that in active-multiple sclerosis, there is a
shift in the lipid composition of NAWM and NAGM to a higher phospholipid and lower sphingolipid content.We
found that this disturbance in lipid composition was reduced in NAGM but not in NAWM of inactive-multiple
sclerosis.The pattern of disturbance in lipid composition suggests a metabolic defectthat causes sphingolipids to
be shuttled to phospholipid production. Modelling the biophysical consequence of this change in lipid composi-
tion of NAWM indicated an increase in the repulsive force between opposing bilayers that could explain decom-
paction and disruption of myelin structure.
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Introduction
Multiple sclerosis is an inflammatory neurodegenerative
condition that is characterized by the demyelination of
axons in discrete regions of the brain and spinal cord.
There is however, ample evidence of more wide spread
damage in the CNS of patients with multiple sclerosis.
Brain imaging studies using diffusion tensor imaging-based
histogram analysis have shown alterations in normal
appearing white matter (NAWM) and normal appearing
grey matter (NAGM) of patients with clinically isolated
syndrome, and even greater disruptions apparent in
patients with relapsing remitting multiple sclerosis
(RRMS) (Chen et al., 2005; Narayanan et al., 2006;
Cudrici et al., 2007; Reich et al., 2007; Yu et al., 2007).
Spectroscopic studies have shown decreased N-acetylaspar-
tate and N-acetyl aspartylglutamate containing compounds
in both clinically isolated syndrome and RRMS and
increased choline and myo-inositol in RRMS (De Stefano
et al., 2002; Tartaglia et al., 2002; Gustafsson et al., 2007;
Wattjes et al., 2007, 2008). These findings suggest that
widespread disruptions in brain biochemistry may contrib-
ute to myelin and axonal damage in tissues that appear
normal on gross examination. Multiple lines of evidence
corroborate findings from brain imaging studies including
findings of cytokine imbalance, oxidative stress, cytoskeletal
damage and neurotransmitter abnormalities (Glabinski et al.,
1993; Semra et al., 2002; Bartosik-Psujek and Stelmasiak,
2006; Skundric et al., 2006; Bartos et al., 2007a, b).
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in myelin bilayers and the importance of lipid content to
biophysical and biochemical properties of membranes, there
has beenlittle research on the content or metabolic processing
of lipids in NAWM and NAGM of multiple sclerosis. There is
a single report from over 30 years ago suggesting that the
sphingosine content of NAWM in multiple sclerosis may be
increased (Moscatelli and Isaacson, 1969) and a more recent
report of reduced sulphatide and increased hydroxylated
sulphatide (h24:0-sulphatide; hydroxy-lignoceroyl sulpha-
tide) in NAWM (Marbois et al., 2000). In an experimental
allergic encephalomyelitis model of multiple sclerosis there is
evidence of increased polyunsaturated lipid content and
phosphatidylserine (PS) (Ohler et al., 2004). These findings
suggest that there may be widespread disruptions of lipid
metabolism in the multiple sclerosis brain that perturbs
membrane asymmetry and myelin structure. To determine if
lipid metabolism is altered, we measured the sphingolipid,
phospholipid and sterol content in NAWM and NAGM of
multiple sclerosis and control brains, and modelled how these
changes would affect the biophysical properties of myelin.
Materials and Methods
Brain tissues
Fresh frozen brain tissues from multiple sclerosis patients and
control brain tissues were obtained from the Rocky Mountain Brain
Bank. Detailed pathological examinations of these tissues were
conducted at the University of Colorado Health Sciences Center,
Department of Pathology. We categorized the multiple sclerosis
tissues used in our studies based on the findings of pathological
exams as active, based on evidence of monocyte infiltrates and
inactive, if there were no infiltrates present. The fresh frozen tissues
used in our biochemical analysis were obtained from middle frontal
gyrus and were adjacent to the regions used for pathological
examinations. All fresh frozen brain tissues used in our analysis were
normal in appearance by gross pathological examination and did not
contain demyelinating lesions. Although we cannot entirely rule out
the possibility that subtle demyelination was present in the tissues
used for our analysis, we did not observe differences in the total lipid
content of multiple sclerosis compared with control tissues. Tissue
samples contained both grey and white matter and were dissected
microscopically into white and grey matter before extraction of
lipids for analysis. Patient demographics were similar in each group:
the active-multiple sclerosis group consisted of six males and six
females with a median age of 48 years (range 24–62 years). The
inactive-multiple sclerosis group consisted of six males and six
females with a median age of 46 years (range 24–60 years). The
control group consisted of five females and six males with a median
age of 49 years (range 33–63 years). Cause of death in the control
group consisted of heart attack (n=4), chronic pulmonary
obstruction (n=4), abdominal aortic aneurism (n=1) and liver
failure (n=2).
Lipid extraction of tissues
Total lipids were then extracted using a modified Bligh and
Dyer procedure as previously described (Haughey et al., 2004).
Purified standards of sphingomyelin C12:0, ceramide C12:0 and
deuterated cholesterol (10 nM each; Avanti Polar Lipids, Alabaster,
AL, USA) were added directly to homogenates. Three volumes of
100% methanol containing 53 mM ammonium formate was added,
and the mixture vortexed. Four volumes of chloroform then were
added, the mixture vortexed and centrifuged at 1000g for 10min.
The chloroform layer was removed into a glass storage vial, flushed
with nitrogen and vial was sealed to be stored at 80C.
Measurement of sphingolipids, phospholipids,
cholesterol and lipid peroxides
Mass spectrometry analyses were performed using a Sciex API 3000
triple stage quadrupole tandem mass spectrometer (ESI/MS/MS)
from Sciex Inc. (Thornhill, Ontario, Canada), using methods similar
to those described in previous studies (Haughey et al., 2004; Bandaru
et al., 2007). Counts were standardized to internal controls described
in the preceding section. Cholesterol and cholesterol ester standards
C16:0, C18:0 and C18:1 were purchased from Sigma (St Louis, MO,
USA). Sphingomyelin and ceramides C16:0, C18:0, C20:0, C22:0,
C24:0, C24:1 were purchased from Avanti Polar Lipids (Alabaster,
AL, USA). 4-Hydroxynonenol and adducts were purchased from
Cayman Chemicals (Ann Arbor, MI, USA).
Immunoblot analyses
Brain tissues were homogenized in ice-cold RIPA buffer consisting
of 62 mM Tris, 2 mM EDTA, 2 mM EGTA, 2% SDS, 10% glycerol
and a protease inhibitor cocktail (Sigma, St Louis, MO, USA), pH
6.0. Proteins (50mg/lane) were separated by SDS–polyacrylamide
gel electrophoresis (10% acrylamide) and transferred to a
nitrocellulose membrane. Membranes were incubated overnight
at 4C with the primary antibodies proteolipid protein (PLP)
(1:200; Millipore, Temecula, CA, USA) or NeuN (1:500; Millipore,
Temecula, CA, USA). Membranes were then exposed to the
appropriate HRP-conjugated secondary antibody (1:3000; Jackson
Immunological Research Laboratories Inc., West Grove, PA, USA)
and immunoreactive proteins were visualized using a chemilumi-
nescene-based detection kit according to the manufacture’s
protocol (ECL kit; Amersham Corp., Arlington Heights, IL, USA).
Data analysis
Heat maps were constructed by a global alignment of the Q3
spectra for all samples. This procedure was used to maximize peak
overlap and correct for small fluctuations in the masses reported
by the instrument. Peaks with average intensities in all three
groups (control, active- and inactive-multiple sclerosis) 5110
6
were considered below the threshold for noise and removed from
analysis. The remaining peaks were evaluated with non-parametric
one-way ANOVA (Kruskal–Wallis test). Peaks with a P-value
40.05 were arbitrarily assigned active-multiple sclerosis: C and
inactive-multiple sclerosis: C ratio = 1 (coded as black). Peaks
with a P-value50.05 were assigned active-multiple sclerosis: C and
inactive-multiple sclerosis: C ratios equal to the fold change
between the active-multiple sclerosis or inactive-multiple sclerosis
and control. Using the program Image J (NIH freeware), a green
colour was used to indicate a ratio41, red if the ratio was51 and
increasing colour intensity to indicate a greater fold change.
Modelling of membrane energetics
A modified Derjaguin–Landau–Verwey–Overbeek (DLVO) theory
was used to model the forces that govern interactions of opposing
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1948). The DLVO model assumes that the energy of adhesion can
be considered as the sum of three independent energies: van
der Waals interactions (lipid species independent), electrostatics
(phosphatydylserine and ceramide dependent) and thermal
undulations (cholesterol and chain length dependent; see
Supplementary Appendix equation 1).
Results
Sphingolipid content of NAWM is decreased
in multiple sclerosis
Cortical tissues from control and multiple sclerosis brains
(healthy appearing tissues) were first separated into white
and grey matter before analysis of lipid content by mass
spectrometry. Western blot results show that after dissection,
white matter samples were immunopositive for the oligo-
dendrocyte marker PLP, and negative for the neuronal
marker NeuN (Fig. 1A). Grey matter samples were negative
for PLP and positive for NeuN (Fig. 1A). ESI/MS/MS
analysis of grey and white matter was conducted to quantify
individual lipid species (Fig. 1B and C). Although myelin is
also found in grey matter (Moll et al., 2008), the amount of
PLP in grey matter is likely insufficient for detection by
Western blot in a side-by-side comparison with white
matter. Qualitative analysis of grey matter showed an overall
loss of sphingolipids in both active- and inactive-multiple
sclerosis. In white matter, there was a loss of select
sphingolipids in active- and inactive-multiple sclerosis and
evidence for increased levels of some sphingolipid species in
active- and inactive-multiple sclerosis (Fig. 2A).
A quantitative analysis of grey matter confirmed
that multiple species of sphingolipid were decreased in
active-multiple sclerosis and only one of the sphingolipid
species we quantified was different from control in
inactive-multiple sclerosis. Sphingolipids decreased only in
active-multiple sclerosis were sphingomyelin C20:0 (57%),
C22:0 (70%), ceramide C18:0 (64%) and C20:0 (69%).
Sphingolipids that were decreased in both active- and
inactive-multiple sclerosis were sphingomyelin C16:0 (67
and 61%, respectively), ceramide C20:0 (81 and 82%) and
C22:0 (83 and 75%) (Fig. 2B and C). In contrast to the
findings from grey matter, a quantitative analysis of
sphingolipids in white matter showed that only a small
number of sphingolipids were decreased in active- or
inactive-multiple sclerosis, however, all sphingolipids
decreased in white matter of active-multiple sclerosis were
also decreased in inactive-multiple sclerosis. Sphingolipids
decreased in active- and inactive-multiple sclerosis were
sphingomyelin C22:0 (35 and 61%, respectively), C24:0
(37 and 67%), ceramide C18:0 (48 and 56%) and C20:0
(53 and 63%) (Fig. 2E and F). These results suggest that
during active-multiple sclerosis, the content of sphingo-
myelin and ceramide in normal appearing brain tissues are
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Fig. 1 Brain dissection and detection of lipids by ESI/MS/MS. (A) Western blot results showing the detection of MBP and the neuronal
marker NeuN in white and grey matter fractions dissected from control brain (B and C). Example MS/MS spectra showing the
identification of sphingomyelin (B) and ceramide (C) from control white matter.
3094 Brain (2008),131, 3092^3102 D.Wheeler et al.decreased and that during periods of disease inactivity,
sphingolipid content of grey matter, but not white matter is
similar to control brain.
Phospholipid content of NAWM and NAGM
is increased in multiple sclerosis
We next determined the phospholipid content of grey and
white matter dissected from normal appearing multiple
sclerosis and control brains. Qualitative analysis of all
phospholipid species present in the precursor scan showed
an overall increase in the phospholipid content in multiple
sclerosis, with the greatest accumulations in the white
matter of active-multiple sclerosis (Fig. 3A). In grey matter
of active- and inactive-multiple sclerosis, there were both
increased and decreased phospholipid species. In white
matter, there was a dramatic increase of multiple phos-
pholipids in active- and inactive-multiple sclerosis, with
comparatively few phospholipids species decreased.
Quantitative analysis of individual phospholipids in grey
matter showed a selective increase of phosphatidylethano-
lamine (PE) in active-multiple sclerosis (from 197% to
225%) that trended toward greater increases in inactive-
multiple sclerosis (388–521%; Fig. 2B and C). In multiple
sclerosis white matter there was increased content of all PE
(152–326% in active-multiple sclerosis and 299–524% in
inactive-multiple sclerosis) and two of five PS species
(327–578% in active-multiple sclerosis and 245–483% in
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Fig. 2 Sphingolipid content of control and multiple sclerosis brain tissues. (A) Sphingolipid array of grey and white matter showing
individual forms of sphingolipid that are decreased (red) and increased (green) in active-multiple sclerosis (Act) or inactive-multiple
sclerosis (Ina) compared with control tissues. (B^E) Quantitative analysis of MRM spectra from grey (B and C)a n dw h i t e( D and E)
matter showing levels of sphingomyelin and ceramide (all are species shown contain a sphingosine C18:1backbone) C16:0^C24:0 in multiple
sclerosis and control brains. Data are mean SD from 8 control and 12 multiple sclerosis brains. ANOVA with Student^Neuman^Keuls
post hoc comparison.
P50.05,
P50.01compared with control.
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Fig. 3 Phospholipid content of control and multiple sclerosis brain. (A) Phospholipid array of grey and white matter showing individual
phospholipids that are decreased (red) and increased (green) in active-multiple sclerosis (Act) or inactive-multiple sclerosis (Ina) compared
with control tissues. (B^E) Quantitative analysis of MRM spectra from grey (B and C)a n dw h i t e( D and E) matter showing levels of PE
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mean SD from 8 control and 12 multiple sclerosis brains. ANOVA with Student^Neuman^Keuls post hoc comparison.
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compared with control.
3096 Brain (2008),131, 3092^3102 D.Wheeler et al.inactive-multiple sclerosis). Similar to the findings in grey
matter, PE trended toward greater accumulations in
inactive- compared with active-multiple sclerosis (Fig. 3D
and E). The phosphtidylcholine (PC) content of grey and
white matter were similar in multiple sclerosis and control
brains with the exception of a single PC analyte that was
increased in grey matter of inactive-multiple sclerosis
(Fig. 1 in Supplementary Appendix).
Cholesterol content of NAWM and NAGM
is reduced in multiple sclerosis
A qualitative analysis of sterols in grey and white matter of
multiple sclerosis showed an overall decrease in the sterol
content of cellular membranes (Fig. 4A). In grey matter,
a number of sterols were decreased in active-multiple
sclerosis, but only one sterol was decreased compared with
control in inactive-multiple sclerosis. In white matter,
a number of sterols were decreased in active- and
inactive-multiple sclerosis. Quantitative analysis of grey
matter spectra showed that the monomeric form of
cholesterol was decreased (67%) in active-multiple sclerosis,
but was not different from control in inactive-multiple
sclerosis (Fig. 4B). In white matter, dimeric (66% decrease)
and trimeric (59% decrease) forms of cholesterol were
depleted in both active- and inactive-multiple sclerosis
(66 and 58% decrease, respectively). Thus, during active-
multiple sclerosis there is a depletion of cholesterol in white
and grey matter. During periods of disease inactivity, sterol
levels of grey matter are not different from control tissues,
while sterol levels in white matter remain lower than controls.
Reactive aldehyde levels are increased in
NAWM of multiple sclerosis
We next sought to determine if lipid peroxidation products
accumulate in normal appearing brain tissues of multiple
sclerosis. Qualitative analysis of the entire spectra clearly
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Fig. 4 Cholesterol content of control and multiple sclerosis brain. (A) Sterol array of grey and white matter showing individual sterols
that are decreased (red) and increased (green) in active-multiple sclerosis (Act) or inactive-multiple sclerosis (Ina) compared with control
tissues. (B^E) Quantitative analysis of MRM spectra from grey (B)a n dw h i t e( C) matter showing levels of monomeric, dimeric, trimeric
and total cholesterol in multiple sclerosis and control brains.Data are mean SD from 8 control and 12 multiple sclerosis brains. ANOVA
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white matter of multiple sclerosis (Fig. 5A). Quantitative
analysis of two 4-hydroxynonenal (4-HNE) species showed
no difference in grey matter of active- or inactive-multiple
sclerosis compared with controls (Fig. 5B). However, in
white matter of active- and inactive-multiple sclerosis, there
were large accumulations of both the lysine and histadine
adducts of 4-HNE (443 and 406%, respectively).
Modelling of membrane energetics
Alterations in the lipid content of cellular membranes can
have dramatic effects on cellular functions by altering in the
biophysical properties of the membrane. We therefore
determined how changes in the sphingolipid, phospholipid
and sterol content of multiple sclerosis white matter could
alter the biophysical properties of myelin. To accomplish
this, we used the DLVO theory to model the forces that
govern interactions of opposing bilayers. The DLVO model
assumes that the energy of adhesion can be considered
as the sum of three independent energies: van der
Waals interactions (lipid species independent), electrostatics
(phosphatydylserine and ceramide dependent) and thermal
undulations (cholesterol and chain length dependent)
(Fig. 6A–C). Because van der Waals energy is independent
of the lipid species it was identical in control and multiple
sclerosis white matter (Fig. 6A and B). The electrostatic
potential decreased from y=44.1mV in control to
y=48.3mV in multiple sclerosis, due to a decreased
content of ceramide and increased content of PS in
multiple sclerosis white matter (Fig. 6A and B). Although
the change in electrostatics raised the adhesion energy, the
dominant destabilizing force resulted from an increased
thermal undulation force; thermal energy in lipid bilayers is
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Fig. 5 Reactive aldehyde levels of control and multiple sclerosis brain. (A) Reactive aldehyde array of grey and white matter showing
individual hydroxynoneals that are decreased (red) and increased (green) in active-multiple sclerosis (Act) or inactive-multiple sclerosis
(Ina) compared with control tissues. (B^C) Quantitative analysis of MRM spectra from grey (B)a n dw h i t e( C) matter showing levels of the
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3098 Brain (2008),131, 3092^3102 D.Wheeler et al.primarily dependent on the degree of chain saturation
(Fig. 6A and B). The bending modulus of lipid bilayer
kc=0.6910
–19J in control white matter, decreased
to kc=0.3910
19J in multiple sclerosis white matter.
These calculations imply that in multiple sclerosis (NAWM)
there is an increase in the magnitude of total repulsive
pressure between myelin bilayers, particularly in the long-
range component of the repulsive pressure that is thought
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withmajordenselines.Inmultiple sclerosis,adecreaseinsphingolipidandincreaseinphospholipidcontentwouldincrease therepulsive energy
attheintraperiodlineanddestabilizemyelin.
Defect of sphingolipid metabolism in multiple sclerosis Brain (2008),131, 3092^3102 3099to be due primarily to thermally induced bilayer undula-
tions (Fig. 6C) (Servuss et al., 1976; Evans and Parsegian,
1986; Bloom et al., 1991). We next calculated the natural
repulsion created by head-to-head arrangement of polar
groups on opposing bilayers of myelin. Assuming a
displacement distance of 4nm, the energy of repulsions
for control tissue was 0.112mJ/m
2 and for multiple sclerosis
tissue 0.869mJ/m
2. Because our model does not account for
protein–lipid interactions, we also calculated the energy of
repulsion using a more conservative displacement distance
of 5nm. When we examined the energetics at 5nm, control
tissue demonstrated an attractive force of 0.0268mJ/m
2
while multiple sclerosis myelin still showed a repulsive force
of 0.385mJ/m
2, consistent with calculations from other
groups (Hu et al., 2004). This additional repulsive energy
would decrease the stability of bonds between layers and
destabilize the structure of myelin.
Discussion
Although the exact causes of multiple sclerosis are not
known, there is increasing evidence of global disruptions in
brain biochemistry that begin early in the course of the
disease and worsen with disease progression. We found that
there is not an overall loss of lipid mass in NAWM or
NAGM, but a reduction in sphingolipid and gain in
phospholipid content that was most prominent during
active disease. The lipid content normalized to a greater
extent in NAGM than NAWM suggesting there may be a
selective defect in the ability of myelin to normalize lipid
content during periods of disease inactivity.
At the core of sphingolipid structure is the long chain
amino alcohol sphingosine. N-acetyl-sphingosine (cera-
mide) is converted to sphingomyelin by sphingomyelin
synthase that adds a phosphorylcholine head group to
ceramide. This is a bi-directional reaction in which
sphingomyelin can be converted back to ceramide by
sphingomyelinase-mediated hydrolysis of sphingomyelin
(see Clarke et al., 2006 for a review). Ceramide can be
further metabolized to sphingosine (by sphingosine kinase),
to sphingosine-1 phosphate (by S1P-phosphohydrolase), to
phosphoethanolamine (by S1P-lyase), to CDP-ethanola-
mine and finally PE (by the Kennedy pathway; Fig. 6D).
A hyperactivation of this pathway in multiple sclerosis is
consistent with our findings of decreased sphingomyelin
and ceramide with increased PE in NAGM, increased PE
and PS in NAWM and no change of PC in either tissue.
Although we can make no definite conclusions on the
enzyme(s) involved, based on our findings of oxidative
damage in the form of 4-HNE modified lysine and
histadine residues in NAWM, it is likely that oxidative
modifications of one or multiple enzymes in this pathway
play roles in shuttling ceramide to the PE/PS pathway. This
conclusion is supported by a lack of evidence for 4-HNE
modified proteins and an absence of excess PS in NAGM of
either active- or inactive-multiple sclerosis, suggesting that
ceramide is not as efficiently shuttled to PE and PS in the
absence of oxidative stress.
If the sphingomyelin–ceramide–sphingosine–S1P pathway
is hyperactive in multiple sclerosis, then it is likely that S1P
levels would also be reduced in NAWM and NAGM. S1P is a
potent endogenous lipid mediator involved in cell survival,
proliferation and cell–cell interactions (see Hait et al., 2006
for a review). S1P-signalling has recently received a great deal
of attention in multiple sclerosis therapy due to the promise
of FTY720 [2-amino-2-[2-(4-octylphenyl) ethyl]propane-
1,3-diol hydrochloride]. This orally available S1P-receptor
modulator has shown striking efficacy in experimental
allergic encephalomyelitis models of multiple sclerosis
(Brinkmann et al., 2002; Fujino et al., 2003; Webb et al.,
2004 Kataoka et al., 2005; Balatoni et al., 2007) and recent
results from phase II trials with RRMS patients are
promising (Kappos et al., 2006). There is additional evidence
that suggests the effectiveness of FTY720 in the CNS extends
beyond immunomodulation to include an influence on
neuronal function, blood–brain barrier and glial repair
mechanisms that could contribute to preservation or
restoration of nerve function (Baumruker et al., 2007; Jung
et al., 2007; Osinde et al., 2007). These results are consistent
with evidence that the bioactive metabolite FTY720-P widely
distributes to the CNS white matter, supporting the
likelihood for functional interaction with glial cells bearing
S1P receptors in the brain and spinal cord (Foster et al.,
2007). Thus, our data are consistent with the notion that
FTY720 may restore S1P-receptor signalling that is lost in
multiple sclerosis due to a hyperactive metabolism of S1P to
phosphoethanolamine, to CDP-ethanolamine and finally PE.
Intramembrane adhesion is critical for myelin to
maintain its compact structure. The head-to-head arrange-
ment of lipids in myelin creates a repulsive energy between
layers that is overcome at the extracellular surfaces (major
dense line) primarily by the stabilizing actions of myelin
basic protein (MBP). Electrostatic interactions between
positively charged surface groups on MBP and negatively
charged PS, combined with attractive van der Waals force
create a highly stable interface. Indeed, the major dense line
is exceptionally stable, even when deliberate attempts are
made to destabilize the structure (Sedzik and Blaurock,
1995). Adhesion at the extracellular surface (intraperiod
line) is less stable and primarily relies on the interactions of
PLP with lipids through van der Waals force to overcome
repulsive energies originating from thermal undulations.
Thus, a change in repulsive energy is more likely to disrupt
adhesion at the intraperiod line, consistent with reports that
this interface is more often disrupted in demyelinating
disease (Bornstein and Raines, 1976; Genain et al., 1999).
Our calculations based on the lipid content of NAWM
indicate that the repulsive energy between bilayers is
increased by an order of magnitude in multiple sclerosis
(Fig. 6E), suggesting that myelin which appears intact on
gross morphological examination has a reduced stability
that would affect its ability to insulate axons. These
3100 Brain (2008),131, 3092^3102 D.Wheeler et al.conclusions are consistent with evidence for widespread
axonal damage early in multiple sclerosis (De Stefano et al.,
2002; Tartaglia et al., 2002; Chen et al., 2005; Narayanan
et al., 2006; Cudrici et al., 2007; Gustafsson et al., 2007;
Reich et al., 2007; Wattjes et al., 2007, 2008; Yu et al.,
2007).
We conclude from our findings that abnormal lipid
metabolism in normal appearing brain tissues may con-
tribute to the pathology of multiple sclerosis by perturbing
the biophysical properties of cellular membranes. The
patterns of change in lipid content that we observed
suggest that deficits in lipid metabolism worsen during
active-multiple sclerosis and modify the lipid composition
of axonal and myelin membranes at sites distant from
lesions. During periods of disease inactivity, axons may
partially normalize lipid content, but a defect in the ability
of myelin to normalize content likely contributes to
progressive widespread damage in multiple sclerosis.
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Supplementary material is available at BRAIN online.
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